S1-RBD
InVivo offers a recombinant form of the spike glycoprotein receptor binding domain (RBD) from severe acute respiratory syndrome-related coronavirus (SARS-CoV-2), Wuhan-Hu-1-isolate (MN908947), which is produced under serum-free conditions in HEK-INV cells (InVivo proprietary optimized; human embryonic kidney, HEK293 cells).
Out of stock
Delivery time: Depending on production time
From: 400,00 € Excl. VAT and delivery costs
Please contact us for larger quantities.
InVivo offers a recombinant form of the spike glycoprotein receptor binding domain (RBD) from severe acute respiratory syndrome-related coronavirus (SARS-CoV-2), Wuhan-Hu-1-isolate (MN908947), which is produced under serum-free conditions in HEK-INV cells (InVivo proprietary optimized; human embryonic kidney, HEK293 cells).
The construct contains 223 residues of the SARS-CoV-2 spike glycoprotein RBD, representing amino acid residues 319 to 541 of before mentioned annotation. The protein includes a Cterminal hexa-histidine tag and is purified using immobilized metal exchange chromatography (IMAC) and preparative SEC (for polishing).
| Product-ID: | S1-RBD_HEK |
|---|---|
| Expression System: | Mammalian; HEK |
| Protein Acession Number: | UniProt: QHD43416.1 |
| Amino Acids: | 319-541 |
| Mature Protein N-Term: | Gln18 (predicted) |
| Tag: | 6 x His-Tag; C-terminal |
| Expected Molecular Weight: | 26 kDa (glycosylated form runs at 40-55 kDa in gel electrophoresis) |
| Formulation: | Liquid ; 20 mM NaPP, 300 mM NaCl pH 7.2 |
| Concentration: | > 1 mg/ml |
| Purity: | > 90% (via analytical CGE under reducing conditions) |
| Aggregation Level: | < 10% (via analytical SEC) |
The product is for research use or for further manufacturing only and not for use in diagnostic or therapeutic procedures.
Additional information
| Document | |
|---|---|
| Notice | The product is for research use or for further manufacturing only and not for use in diagnostic or therapeutic procedures. |
You must be logged in to post a review.
Reviews
There are no reviews yet.